Drug Criteria & Outcomes: In the Pipeline
June 1, 2002
Drug Criteria & Outcomes: In the Pipeline
Alexion Pharmaceuticals and its partner Procter & Gamble Pharmaceuticals have completed enrollment of approximately 900 patients in their second Phase II acute myocardial infarction trial with pexelizumab.
Nobex Corp. and Elan Corp. announced that their joint venture, Synerobex, has initiated dosing in a Phase I clinical trial in the development and commercialization of oral calcitonin (Oratonin), for the treatment of osteoporosis.
Transgene has initiated a Phase II clinical trial of its immunotherapeutic MVA-Muc1-IL2 vaccine candidate for the treatment of prostate cancer.
Telik announced the initiation of a Phase II clinical trial of its TLK286 product candidate in breast cancer. This is the first TLK286 Phase II trial in breast cancer as well as the first Phase II trial in which TLK286 is being administered on a weekly dosing schedule.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content